Dr Ulrich Müller
University position
Lecturer
Dr Ulrich Müller is pleased to consider applications from prospective PhD students.
Departments
Institutes
Behavioural and Clinical Neuroscience Institute
Research Themes
Interests
My major research interest is the neurotransmitter modulation of cognitive and emotional processes, with a focus on the role of dopamine and noradrenaline in frontostriatal functions. I use fMRI, radioligand imaging with PET, pharmacological challenges and genetic testing for neurotransmitter polymorphisms in combination with working memory and other prefrontal tasks in healthy volunteers and patients with attention deficit hyperactivity disorder (ADHD), schizophrenia and other neuropsychiatric diseases. The aim of this research is to develop pharmacological and behavioural strategies to improve cognitive functions in patients with ADHD and schizophrenia.
I am a honorary consultant psychiatrist with Cambridgeshire and Peterborough NHS Foundation Trust and director of the Adult ADHD Research Clinic.
Research Focus
Keywordsdopamine working memory ADHD noradrenaline prefrontal |
Clinical conditionsAttention deficit hyperactivity disorder Cognitive impairment Schizophrenia |
Equipment
Magnetic resonance imaging (MRI)
Neuropsychological testing
Positron Emission Tomography (PET)
Collaborators
Cambridge | United KingdomJonathan Roiser Web: http://www.ion.ucl.ac.uk/ InternationalRoshan Cools Web: http://www.roshancools.com/ Hesse Swen Web: http://www.uni-leipzig.de/english... |
Key publications
Seixas M, Weiss M, Müller U (2012), “Systematic review of national and international guidelines on attention-deficit hyperactivity disorder.” J Psychopharmacol 26(6):753-65 Details
Dodds CM, Müller U, Clark L, van Loon A, Cools R, Robbins TW (2008), “Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning.” J Neurosci 28(23):5976-82 PDF Details
Barnett JH, Jones PB, Robbins TW, Müller U (2007), “Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls.” Mol Psychiatry 12(5):502-9 Details
Chamberlain SR, Müller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006), “Neurochemical modulation of response inhibition and probabilistic learning in humans.” Science 311(5762):861-3 PDF Details
Müller U, Steffenhagen N, Regenthal R, Bublak P (2004), “Effects of modafinil on working memory processes in humans.” Psychopharmacology (Berl) 177(1-2):161-9 Details
Publications
2013
Adamou M, Arif M, Asherson P, Aw TC, Bolea B, Coghill D, Guðjónsson G, Halmøy A, Hodgkins P, Müller U, Pitts M, Trakoli A, Williams N, Young S (2013), “Occupational issues of adults with ADHD.” BMC Psychiatry 13(1):59 Details
Crockett MJ, Apergis-Schoute A, Herrmann B, Lieberman M, Müller U, Robbins TW, Clark L (2013), “Serotonin Modulates Striatal Responses to Fairness and Retaliation in Humans.” J Neurosci 33(8):3505-3513 Details
Kuhlmei A, Walther B, Becker T, Müller U, Nikolaus T (2013), “Actigraphic daytime activity is reduced in patients with cognitive impairment and apathy.” Eur Psychiatry 28(2):94-7 Details
Müller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ (2013), “Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers.” Neuropharmacology 64(1):490-5 Details
2012
Bolea B, Adamou M, Arif M, Asherson P, Gudjonsson G, Müller U, Nutt Dj, Pitts M, Thome J, Young S (2012), “ADHD matures: time for practitioners to do the same?” J Psychopharmacol 26(6):766-70 PDF Details
Caisley H, Müller U (2012), “Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: A systematic review.” Eur Psychiatry 27(5):343-9 Details
Coogan AN, Dobrean A, Donev RM, Mateescu L, Müller U, Thome J, Voinescu BI (2012), “Adult attention deficit hyperactivity disorder: translating research into practice.” Atten Defic Hyperact Disord PDF Details
Del Campo N, Müller U, Sahakian BJ (2012), “Neural and behavioral endophenotypes in ADHD.” Curr Top Behav Neurosci 11:65-91 Details
Ersche KD, Cumming P, Craig KJ, Müller U, Fineberg NA, Bullmore ET, Robbins TW (2012), “Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?” J Psychopharmacol 26(6):887-90 Details
Ersche KD, Turton AJ, Chamberlain SR, Müller U, Bullmore ET, Robbins TW (2012), “Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence.” Am J Psychiatry 169(9):926-36 Details
Magon U, Müller U (2012), “ADHD with comorbid substance use disorder: review of treatment” Advances in Psychiatric Treatment 18: 436-446
Müller U, Asherson P (2012), “Addressing common misconceptions about attention deficit hyperactivity disorder in adults” Neuropsychiatry 2: 185-188 PDF
Zaman R, Arif M, Vaze A, Müller U (2012), “Setting up adult ADHD services in the United Kingdom” Cutting Egde Psychiatry in Practice 2: 170-175 PDF
2011
Blanchard MM, Chamberlain SR, Roiser J, Robbins TW, Müller U (2011), “Effects of two dopamine-modulating genes ( DAT1 9/10 and COMT Val/Met) on n-back working memory performance in healthy volunteers.” Psychol Med 41(3):611-8 Details
Chamberlain SR, Robbins TW, Winder-Rhodes S, Müller U, Sahakian BJ, Blackwell AD, Barnett JH (2011), “Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery.” Biol Psychiatry 69(12):1192-203 Details
Costa A, Riedel M, Müller U, Möller HJ, Ettinger U (2011), “Relationship between SLC6A3 genotype and striatal dopamine transporter availability: A meta-analysis of human single photon emission computed tomography studies.” Synapse Details
Del Campo N, Tait RJ, Acosta-Cabronero J, Hong YT, Izquierdo-Garcia D, Smith R, Aigbirhio FI, Sahakian BJ, Müller U, Robbins TW, Fryer TD (2011), “Quantification of receptor-ligand binding potential in sub-striatal domains using probabilistic and template regions of interest.” Neuroimage 55(1):101-12 Details
Ersche KD, Roiser JP, Abbott S, Craig KJ, Müller U, Suckling J, Ooi C, Shabbir SS, Clark L, Sahakian BJ, Fineberg NA, Merlo-Pich EV, Robbins TW, Bullmore ET (2011), “Response perseveration in stimulant dependence is associated with striatal dysfunction and can be ameliorated by a D(2/3) receptor agonist.” Biol Psychiatry 70(8):754-62 Details
Finke K, Schwarzkopf W, Müller U, Frodl T, Müller HJ, Schneider WX, Engel RR, Riedel M, Möller HJ, Hennig-Fast K (2011), “Disentangling the adult attention-deficit hyperactivity disorder endophenotype: Parametric measurement of attention.” J Abnorm Psychol 120(4):890-901 Details
Valenzuela M, Bartrés-Faz D, Beg F, Fornito A, Merlo-Pich E, Müller U, Ongür D, Toga AW, Yücel M (2011), “Neuroimaging as endpoints in clinical trials: Are we there yet? Perspective from the first Provence workshop.” Mol Psychiatry 16(11):1064-6 Details
Young SJ, Adamou M, Bolea B, Gudjonsson G, Muller U, Pitts M, Thome J, Asherson P (2011), “The identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agencies.” BMC Psychiatry 11(1):32 Details
2010
Asherson P, Adamou M, Bolea B, Muller U, Morua SD, Pitts M, Thome J, Young S (2010), “Is ADHD a valid diagnosis in adults? Yes.” BMJ 340:c549 Details
Chamberlain SR, Grant JE, Costa A, Müller U, Sahakian BJ (2010), “Effects of acute modafinil on cognition in trichotillomania.” Psychopharmacology (Berl) 212(4):597-601 Details
Ersche KD, Bullmore ET, Craig KJ, Shabbir SS, Abbott S, Müller U, Ooi C, Suckling J, Barnes A, Sahakian BJ, Merlo-Pich EV, Robbins TW (2010), “Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence.” Arch Gen Psychiatry 67(6):632-44 Details
Finke K, Dodds CM, Bublak P, Regenthal R, Baumann F, Manly T, Müller U (2010), “Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study.” Psychopharmacology (Berl) 210(3):317-29 Details
Lynall ME, Bassett DS, Kerwin R, McKenna PJ, Kitzbichler M, Muller U, Bullmore E (2010), “Functional connectivity and brain networks in schizophrenia.” J Neurosci 30(28):9477-87 PDF Details
Morein-Zamir S, Craig KJ, Ersche KD, Abbott S, Muller U, Fineberg NA, Bullmore ET, Sahakian BJ, Robbins TW (2010), “Impaired visuospatial associative memory and attention in obsessive compulsive disorder but no evidence for differential dopaminergic modulation.” Psychopharmacology (Berl) 212(3):357-67 Details
Roesch-Ely D, Pfueller U, Mundt C, Müller U, Weisbrod M (2010), “[Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies]” Nervenarzt 81(5):564-76 Details
Winder-Rhodes SE, Chamberlain SR, Idris MI, Robbins TW, Sahakian BJ, Müller U (2010), “Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers.” J Psychopharmacol 24(11):1649-57 Details
2009
Chamberlain SR, Hampshire A, Müller U, Rubia K, Del Campo N, Craig K, Regenthal R, Suckling J, Roiser JP, Grant JE, Bullmore ET, Robbins TW, Sahakian BJ (2009), “Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study.” Biol Psychiatry 65(7):550-5 Details
Dodds C, Müller U, Manly T (2009), “Effects of psychostimulants on alertness and spatial bias in healthy participants.” J Cogn Neurosci 21(3):529-37 Details
Dodds CM, Clark L, Dove A, Regenthal R, Baumann F, Bullmore E, Robbins TW, Müller U (2009), “The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory.” Psychopharmacology (Berl) 207(1):35-45 PDF Details
Müller U, Roesch-Ely D (2009), “Can we treat cognitive impairment in schizophrenia?” In: Gallhofer B, Eberhard J (eds.) Controversies in Cognition: From Laboratory and Testing to Better Functioning. Lundbeck, Copenhagen, pp 47-59
Ullsperger M, Müller U (2009), “Pharmakologische Interventionen in der Klinischen Neuropsychologie” In: Sturm H, Herrmann M, Münte T (eds) Lehrbuch der Klinischen Neuropsychologie: Grundlagen, Methoden, Diagnostik, Therapie. 2. Auflage. Spektrum Akademischer Verlag, Heidelberg, pp 843-858
2008
Chamberlain SR, Menzies LA, Fineberg NA, Del Campo N, Suckling J, Craig K, Müller U, Robbins TW, Bullmore ET, Sahakian BJ (2008), “Grey matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study.” Br J Psychiatry 193(3):216-21 Details
Müller U (2008), “Pharmacological treatment” In: Cappa SF, Abutalebi J, Démonet J-F, Fletcher P, Garrard P (eds.) Cognitive Neurology: A Clinical Textbook. Oxford University Press, Oxford, pp 475-498
Müller U, Becker T (2008), “Kognition und Rehabilitation” In: Kircher TT, Gauggel S (eds.) Neuropsychologie der Schizophrenie. Springer, Heidelberg, pp 613-623
2007
Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW, Sahakian BJ (2007), “Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.” Biol Psychiatry 62(9):977-84 Details
Chamberlain SR, Müller U, Cleary S, Robbins TW, Sahakian BJ (2007), “Atomoxetine increases salivary cortisol in healthy volunteers.” J Psychopharmacol 21(5):545-9 Details
Chamberlain SR, Müller U, Deakin JB, Corlett PR, Dowson J, Cardinal RN, Aitken MR, Robbins TW, Sahakian BJ (2007), “Lack of deleterious effects of buspirone on cognition in healthy male volunteers.” J Psychopharmacol 21(2):210-5 Details
Roiser JP, Müller U, Clark L, Sahakian BJ (2007), “The effects of acute tryptophan depletion and serotonin transporter polymorphism on emotional processing in memory and attention.” Int J Neuropsychopharmacol 10(4):449-61 Details
2006
Chamberlain SR, Müller U, Blackwell AD, Robbins TW, Sahakian BJ (2006), “Noradrenergic modulation of working memory and emotional memory in humans.” Psychopharmacology (Berl) 188(4):397-407 Details
Chamberlain SR, Müller U, Robbins TW, Sahakian BJ (2006), “Neuropharmacological modulation of cognition.” Curr Opin Neurol 19(6):607-12 Details
Müller U, Czymmek J, Thöne-Otto A, Von Cramon DY (2006), “Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy.” Brain Inj 20(2):157-60 Details
Müller U, Fletcher PC, Steinberg H (2006), “The origin of pharmacopsychology: Emil Kraepelin's experiments in Leipzig, Dorpat and Heidelberg (1882-1892).” Psychopharmacology (Berl) 184(2):131-8 Details
Stengler-Wenzke K, Müller U, Barthel H, Angermeyer MC, Sabri O, Hesse S (2006), “Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.” Neuropsychobiology 53(1):40-5 Details
2005
Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K (2005), “Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder.” Psychiatry Res 140(1):63-72 Details
Müller U (2005), “Somatische Behandlungsverfahren mit rehabilitativem Charakter” In: Frieboes RM, Zaudig M, Nosper M (eds) Rehabilitation bei psychischen Störungen. Elsevier/Urban & Fischer, München, pp 110-134
Müller U, Clark L, Lam ML, Moore RM, Murphy CL, Richmond NK, Sandhu RS, Wilkins IA, Menon DK, Sahakian BJ, Robbins TW (2005), “Lack of effects of guanfacine on executive and memory functions in healthy male volunteers.” Psychopharmacology (Berl) 182(2):205-13 Details
Müller U, Mottweiler E, Bublak P (2005), “Noradrenergic blockade and numeric working memory in humans.” J Psychopharmacol 19(1):21-8 Details
Müller U, Suckling J, Zelaya F, Honey G, Faessel H, Williams SC, Routledge C, Brown J, Robbins TW, Bullmore ET (2005), “Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes.” Psychopharmacology (Berl) 180(4):624-33 Details
Müller U, Ullsperger M, Hammerstein E, Sachweh S, Becker T (2005), “Directed forgetting in schizophrenia: prefrontal memory and inhibition deficits.” Eur Arch Psychiatry Clin Neurosci 255(4):251-7 Details
Müller U, Werheid K, Hammerstein E, Jungmann S, Becker T (2005), “Prefrontal cognitive deficits in patients with schizophrenia treated with atypical or conventional antipsychotics.” Eur Psychiatry 20(1):70-3 Details
Steinberg H, Müller U (2005), “Emil Kraepelin 1882/83 in Leipzig und seine frühen pharmakopsychologischen Arbeiten im Lichte der aktuellen Forschung” In: Angermeyer M, Steinberg H (eds) 200 Jahre Psychiatrie an der Universität Leipzig: Personen und Konzepte. Springer, Heidelberg, pp 121-154
2004
Hensel A, Ibach B, Muller U, Kruggel F, Kiefer M, Gertz HJ (2004), “Does the pattern of atrophy of the Corpus callosum differ between patients with frontotemporal dementia and patients with Alzheimer's disease?” Dement Geriatr Cogn Disord 18(1):44-9 Details
Hesse S, Barthel H, Schwarz J, Sabri O, Müller U (2004), “Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders.” Neurosci Biobehav Rev 28(6):547-63 Details
Stengler-Wenzke K, Müller U, Angermeyer MC, Sabri O, Hesse S (2004), “Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD).” Eur Arch Psychiatry Clin Neurosci 254(4):252-5 Details
2003
Hesse S, Barthel H, Murai T, Müller U, Müller D, Seese A, Kluge R, Sabri O (2003), “Is correction for age necessary in neuroimaging studies of the central serotonin transporter?” Eur J Nucl Med Mol Imaging 30(3):427-30 Details
Müller U, Wolf H, Kiefer M, Gertz HJ (2003), “[A systematic comparison of national and international dementia guidelines]” Fortschr Neurol Psychiatr 71(6):285-95 Details
Murai T, Barthel H, Berrouschot J, Sorger D, von Cramon DY, Müller U (2003), “Neuroimaging of serotonin transporters in post-stroke pathological crying.” Psychiatry Res 123(3):207-11 Details
Stengler-Wenzke K, Müller U, Matthes-von-Cramon G (2003), “[Compulsive-obsessive disorder after severe head trauma: diagnosis and treatment]” Psychiatr Prax 30(1):37-9 Details
2002
Bublak P, Müller U, Grön G, Reuter M, von Cramon DY (2002), “Manipulation of working memory information is impaired in Parkinson's disease and related to working memory capacity.” Neuropsychology 16(4):577-90 Details
Müller U, Reuter M, Hermann W, Gertz HJ (2002), “[Levodopa dependency in Parkinson's disease: case report and review]” Nervenarzt 73(9):887-91 Details
Schubert T, Volkmann J, Müller U, Sturm V, Voges J, Freund HJ, Von Cramon DY (2002), “Effects of pallidal deep brain stimulation and levodopa treatment on reaction-time performance in Parkinson's disease.” Exp Brain Res 144(1):8-16 Details
Stengler-Wenzke K, Müller U (2002), “Fluoxetine for OCD after brain injury.” Am J Psychiatry 159(5):872 Details
Werheid K, Hoppe C, Thöne A, Müller U, Müngersdorf M, von Cramon DY (2002), “The Adaptive Digit Ordering Test: clinical application, reliability, and validity of a verbal working memory test.” Arch Clin Neuropsychol 17(6):547-65 Details
2001
Murai T, Müller U, Werheid K, Sorger D, Reuter M, Becker T, von Cramon DY, Barthel H (2001), “In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease.” J Neuropsychiatry Clin Neurosci 13(2):222-8 Details
Schneider S, Müller U (2001), “[Synaesthesia - towards a cognitive neuroscience of coloured hearing]” Fortschr Neurol Psychiatr 69(11):532-8 Details
2000
Barthel H, Müller U, Wächter T, Slomka P, Dannenberg C, Murai T, Kahn T, Georgi P (2000), “[Multimodal SPECT and MRT imaging data analysis for an improvement in the diagnosis of idiopathic Parkinson's syndrome]” Radiologe 40(10):863-9 Details
Hoppe CD, Müller UD, Werheid KD, Thöne AD, von Cramon YD (2000), “Digit Ordering Test: clinical, psychometric, and experimental evaluation of a verbal working memory test.” Clin Neuropsychol 14(1):38-55 Details
Müller U, Wächter T, Barthel H, Reuter M, von Cramon DY (2000), “Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease.” J Neural Transm 107(3):303-19 Details
Ullsperger M, Mecklinger A, Müller U (2000), “An electrophysiological test of directed forgetting: the role of retrieval inhibition.” J Cogn Neurosci 12(6):924-40 Details
1999
Frieboes RM, Müller U, Murck H, von Cramon DY, Holsboer F, Steiger A (1999), “Nocturnal hormone secretion and the sleep EEG in patients several months after traumatic brain injury.” J Neuropsychiatry Clin Neurosci 11(3):354-60 Details
Müller U (1999), “Pharmakologie” In: Frommelt P, Grötzbach H (eds) Neuro-Rehabilitation: Grundlagen, Praxis, Dokumentation. Blackwell, Berlin, pp 541-551
Müller U, Murai T, Bauer-Wittmund T, von Cramon DY (1999), “Paroxetine versus citalopram treatment of pathological crying after brain injury.” Brain Inj 13(10):805-11 Details
1998
Becker T, Müller U (1998), “Relevance of brain imaging studies for social psychiatry.” Epidemiol Psichiatr Soc 7(2):89-93 Details
Müller U, von Cramon DY, Pollmann S (1998), “D1- versus D2-receptor modulation of visuospatial working memory in humans.” J Neurosci 18(7):2720-8 PDF Details
von Cramon DY, Müller U (1998), “The septal region and memory.” Adv Tech Stand Neurosurg 24:3-40 Details
1996
Müller U, Frieboes R, von Cramon DY (1996), “Diagnose und Therapie emotionaler Instabilität nach Hirninfarkt” In: Möller HJ, Müller-Spahn F, Kurtz G (eds) Aktuelle Perspektiven der Biologischen Psychiatrie. Springer, Wien, pp 112-116
1994
Müller U, von Cramon DY (1994), “The therapeutic potential of bromocriptine in neuropsychological rehabilitation of patients with acquired brain damage.” Prog Neuropsychopharmacol Biol Psychiatry 18(7):1103-20 Details
1992
Weller M, Müller U, Kornhuber J (1992), “Paranoid psychosis, epidermoid tumor, and epilepsy: "symptomatic" psychosis or coincidence?” J Clin Psychiatry 53(7):257-8 Details
1989
Lesch KP, Müller U, Rupprecht R, Kruse K, Schulte HM (1989), “Endocrine responses to growth hormone-releasing hormone, thyrotropin-releasing hormone and corticotropin-releasing hormone in depression.” Acta Psychiatr Scand 79(6):597-602 Details
Rupprecht R, Lesch KP, Müller U, Beck G, Beckmann H, Schulte HM (1989), “Blunted adrenocorticotropin but normal beta-endorphin release after human corticotropin-releasing hormone administration in depression.” J Clin Endocrinol Metab 69(3):600-3 Details


